{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:43:31Z","timestamp":1793202211163,"version":"4.5.0"},"reference-count":67,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2016,10,27]]},"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:p>Guillain-Barr\u00e9 syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical course and outcome. Intravenous immunoglobulin (IVIg) and plasma exchange are proven effective treatments, but the efficacy has been demonstrated mainly on motor improvement in adults with a typical and severe form of GBS. In clinical practice, treatment dilemmas may occur in patients with a relatively mild presentation, variant forms of GBS, or when the onset of weakness was more than 2\u2005weeks ago. Other therapeutic dilemmas may arise in patients who do not improve or even progress after initial treatment. We provide an overview of the current literature about therapeutic options in these situations, and additionally give our personal view that may serve as a basis for therapeutic decision-making.<\/jats:p>","DOI":"10.1136\/jnnp-2016-314862","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T04:14:52Z","timestamp":1478924092000},"page":"346-352","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":93,"title":["Treatment dilemmas in Guillain-Barr\u00e9 syndrome"],"prefix":"10.1136","volume":"88","author":[{"given":"Christine","family":"Verboon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart C","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"key":"2024031200251423000_88.4.346.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121"},{"key":"2024031200251423000_88.4.346.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1"},{"key":"2024031200251423000_88.4.346.3","doi-asserted-by":"crossref","unstructured":"Raphael JC , Chevret S , Hughes RA , et al . Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2012;(7):CD001798. doi:10.1002\/14651858.CD001798.pub2","DOI":"10.1002\/14651858.CD001798.pub2"},{"key":"2024031200251423000_88.4.346.4","doi-asserted-by":"crossref","unstructured":"Hughes RA , Swan AV , van Doorn PA . Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev 2014 (9):CD002063. doi:10.1002\/14651858.CD002063.pub6","DOI":"10.1002\/14651858.CD002063.pub6"},{"key":"2024031200251423000_88.4.346.5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm004"},{"key":"2024031200251423000_88.4.346.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.5.605"},{"key":"2024031200251423000_88.4.346.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182904fcc"},{"key":"2024031200251423000_88.4.346.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181f88345"},{"key":"2024031200251423000_88.4.346.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92644-2"},{"key":"2024031200251423000_88.4.346.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"2024031200251423000_88.4.346.11","doi-asserted-by":"crossref","unstructured":"Hughes RA , Pritchard J , Hadden RD . Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2013;(2):CD008630. doi:10.1002\/14651858.CD008630.pub3","DOI":"10.1002\/14651858.CD008630.pub3"},{"key":"2024031200251423000_88.4.346.12","doi-asserted-by":"crossref","unstructured":"Hughes RA , van Doorn PA . Corticosteroids for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev 2012;(8):CD001446. doi:10.1002\/14651858.CD001446.pub4","DOI":"10.1002\/14651858.CD001446.pub4"},{"key":"2024031200251423000_88.4.346.13","doi-asserted-by":"crossref","unstructured":"Khan F , Ng L , Amatya B , et al . Multidisciplinary care for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev 2010 (10):CD008505. doi:10.1002\/14651858.CD008505.pub2","DOI":"10.1002\/14651858.CD008505"},{"key":"2024031200251423000_88.4.346.14","doi-asserted-by":"crossref","unstructured":"Overell JR , Hsieh ST , Odaka M , et al . Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007 (1):CD004761. doi:10.1002\/14651858.CD004761.pub2","DOI":"10.1002\/14651858.CD004761.pub2"},{"key":"2024031200251423000_88.4.346.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540080059030"},{"key":"2024031200251423000_88.4.346.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.15.1987"},{"key":"2024031200251423000_88.4.346.17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.8.1096"},{"key":"2024031200251423000_88.4.346.18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220612"},{"key":"2024031200251423000_88.4.346.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra993360"},{"key":"2024031200251423000_88.4.346.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.04.002"},{"key":"2024031200251423000_88.4.346.21","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt285"},{"key":"2024031200251423000_88.4.346.22","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1992.00530300044009"},{"key":"2024031200251423000_88.4.346.23","doi-asserted-by":"crossref","unstructured":"Eftimov F , Winer JB , Vermeulen M , et al . Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013 (12):CD001797. doi:10.1002\/14651858.CD001797.pub3","DOI":"10.1002\/14651858.CD001797.pub3"},{"key":"2024031200251423000_88.4.346.24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.620"},{"key":"2024031200251423000_88.4.346.25","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1212\/WNL.58.4.610","article-title":"Infections and course of disease in mild forms of Guillain-Barr\u00e9 syndrome","volume":"58","author":"Van Koningsveld","year":"2002","journal-title":"Neurology"},{"key":"2024031200251423000_88.4.346.26","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1324"},{"key":"2024031200251423000_88.4.346.27","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410304"},{"key":"2024031200251423000_88.4.346.28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/ern.11.182","article-title":"Fisher syndrome: clinical features, immunopathogenesis and management","volume":"12","author":"Mori","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"2024031200251423000_88.4.346.29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.8.1104"},{"key":"2024031200251423000_88.4.346.30","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.wnl.0000258673.31824.61","article-title":"Intravenous immunoglobulin therapy for Miller Fisher syndrome","volume":"68","author":"Mori","year":"2007","journal-title":"Neurology"},{"key":"2024031200251423000_88.4.346.31","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/jnnp.72.5.680","article-title":"Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases","volume":"72","author":"Mori","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024031200251423000_88.4.346.32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.154351"},{"key":"2024031200251423000_88.4.346.33","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/ene.12983","article-title":"How often and when Fisher syndrome is overlapped by Guillain-Barr\u00e9 syndrome or Bickerstaff brainstem encephalitis?","volume":"23","author":"Sekiguchi","year":"2016","journal-title":"Eur J Neurol"},{"key":"2024031200251423000_88.4.346.34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5032.1384"},{"key":"2024031200251423000_88.4.346.35","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302824"},{"key":"2024031200251423000_88.4.346.36","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg233"},{"key":"2024031200251423000_88.4.346.37","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/118.4.841"},{"key":"2024031200251423000_88.4.346.38","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200003)47:3<314::AID-ANA6>3.0.CO;2-C"},{"key":"2024031200251423000_88.4.346.39","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4598(200101)24:1<54::AID-MUS6>3.0.CO;2-9"},{"key":"2024031200251423000_88.4.346.40","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410400209"},{"key":"2024031200251423000_88.4.346.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70215-1"},{"key":"2024031200251423000_88.4.346.42","doi-asserted-by":"crossref","unstructured":"Hughes RA , Swan AV , van Doorn PA . Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2012;(7):CD002063. doi:10.1002\/14651858.CD002063.pub5","DOI":"10.1002\/14651858.CD002063.pub5"},{"key":"2024031200251423000_88.4.346.43","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440512"},{"key":"2024031200251423000_88.4.346.44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00365549509019016","article-title":"Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome","volume":"27","author":"G\u00fcrses","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"2024031200251423000_88.4.346.45","doi-asserted-by":"publisher","DOI":"10.1186\/cc10305"},{"key":"2024031200251423000_88.4.346.46","first-page":"223","article-title":"Intravenous immunoglobulin therapy in children with Guillain-Barr\u00e9 syndrome","volume":"16","author":"Wang","year":"2001","journal-title":"J Applied Clinical Pediatrics"},{"key":"2024031200251423000_88.4.346.47","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1537-2995.2007.01405.x","article-title":"Complications of apheresis in children","volume":"47","author":"Michon","year":"2007","journal-title":"Transfusion"},{"key":"2024031200251423000_88.4.346.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261705"},{"key":"2024031200251423000_88.4.346.49","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.100"},{"key":"2024031200251423000_88.4.346.50","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0140-6736(84)91341-2","article-title":"Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy","volume":"1","author":"Greenwood","year":"1984","journal-title":"Lancet"},{"key":"2024031200251423000_88.4.346.51","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(84)90819-5","article-title":"Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy","volume":"2","author":"Osterman","year":"1984","journal-title":"Lancet"},{"key":"2024031200251423000_88.4.346.52","doi-asserted-by":"publisher","DOI":"10.1159\/000050777"},{"key":"2024031200251423000_88.4.346.53","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.2.235"},{"key":"2024031200251423000_88.4.346.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15324-X"},{"key":"2024031200251423000_88.4.346.55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CND.0b013e3181f3dbbf","article-title":"Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barr\u00e9 syndrome: critical reassessment of effectiveness and cost-efficiency","volume":"12","author":"Oczko-Walker","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"2024031200251423000_88.4.346.56","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21737"},{"key":"2024031200251423000_88.4.346.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)24050-X"},{"key":"2024031200251423000_88.4.346.58","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2009.171702"},{"key":"2024031200251423000_88.4.346.59","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm316"},{"key":"2024031200251423000_88.4.346.60","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02493725?term=guillain+barre+AND+eculizumab&rank=2"},{"key":"2024031200251423000_88.4.346.61","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02029378?term=eculizumab+guillain%5C&rank=1"},{"key":"2024031200251423000_88.4.346.62","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2000.00096.x"},{"key":"2024031200251423000_88.4.346.63","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/01.WNL.0000092019.53628.88","article-title":"A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barr\u00e9 syndrome","volume":"61","author":"Pritchard","year":"2003","journal-title":"Neurology"},{"key":"2024031200251423000_88.4.346.64","first-page":"332","article-title":"[Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome]","volume":"20","author":"Zhang","year":"2000","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"2024031200251423000_88.4.346.65","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1212\/WNL.57.5.774","article-title":"CSF filtration is an effective treatment of Guillain-Barr\u00e9 syndrome: a randomized clinical trial","volume":"57","author":"Wollinsky","year":"2001","journal-title":"Neurology"},{"key":"2024031200251423000_88.4.346.66","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.11.957"},{"key":"2024031200251423000_88.4.346.67","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e07d14"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2016-314862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T07:25:44Z","timestamp":1710228344000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2016-314862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,3,17]]},"published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1136\/jnnp-2016-314862"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2016-314862","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]}}}